Malignant gliomas consist of glioblastomas, anaplastic astrocytomas, anaplastic
oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such …

The current method for assessing the response to therapy of glial tumors was described by
Macdonald et al. in 1990. Under this paradigm, response categorization is determined on …

Magnetic resonance imaging is integral to the care of patients with high-grade gliomas.
Anatomic detail can be acquired with conventional structural imaging, but newer …

The Response Assessment in Neuro-Oncology criteria were developed as an objective tool
for radiologic assessment of treatment response in high-grade gliomas. Imaging plays a …

Advances in understanding the molecular underpinnings of cancer and in molecular
diagnostic technologies have changed the clinical practice of oncologic pathology. The …

Recent advances in the treatment of cerebral gliomas have increased the demands on
noninvasive neuroimaging for the diagnosis, therapeutic planning, tumor monitoring, and …

Objective Summarize evidence for use of advanced MRI techniques as monitoring
biomarkers in the clinic, and highlight the latest bench-to-bedside developments. Methods …

Currently, the most widely used criteria for assessing response to therapy in high-grade
gliomas are based on two-dimensional tumor measurements on computed tomography (CT) …

Gliomas, a prevalent category of primary malignant brain tumors, pose formidable clinical
challenges due to their invasive nature and limited treatment options. The current …

Over the past 20 years, very few agents have been approved for the treatment of brain
tumors. Recent studies have highlighted some of the challenges in assessing activity in …